Skip to Content

New Graft Strategy May Improve Outcomes for Blood Stem Cell Recipients

January 12, 2022

Removing one type of T cell from donor blood used for stem cell grafts could greatly reduce a serious complication called graft-versus-host disease in patients with leukemia, according to a new study.

Published in the Journal of Clinical Oncology, the study reports that only 7% of leukemia patients who received stem cell transplants depleted of naïve T cells developed chronic graft-versus-host disease, or GVHD, as compared to the 30% to 60% rate with standard of care treatment. About 70% of these patients developed the acute form of GVHD, but disease was typically mild and responsive to first-line corticosteroid agents.

Warren Shlomchik release“It’s quite remarkable that we were able to reduce chronic GVHD so dramatically with this graft engineering strategy,” said senior author Warren Shlomchik, MD, director of the Hematopoietic Stem Cell Transplant and Cell Therapy program at UPMC Hillman Cancer Center, and professor of medicine and immunology at the University of Pittsburgh School of Medicine. “It’s also striking that we saw almost no steroid-refractory acute graft-versus-host disease in our patients.”

For patients with leukemia and other blood diseases, transplantation of hematopoietic stem cells — progenitor cells that can turn into any type of blood cell — from a healthy donor can rebuild the body’s blood manufacturing system. But this life-saving treatment also comes with risks. Stem cell grafts, which are collected from either the bone marrow or circulating blood, contain T cells that can cause GVHD by attacking host tissues.

Acute GVHD typically occurs within 100 days after transplantation and tends to affect the skin, liver and gastrointestinal tract. Most patients respond to corticosteroid drugs, but a substantial fraction require additional immunosuppression. Chronic GVHD usually develops later than the acute form and can affect many organs. This persistent version of the disease can be more difficult to treat, often requiring prolonged immunosuppression and reducing patient quality of life or causing death.

Removing all T cells from a graft prior to transplantation can reduce GVHD, but this approach is a double-edged sword. Previous studies found that patients were at higher risk of leukemia relapse or death because T cells also are important for killing cancer cells and fighting infections.  

Shlomchik and colleagues’ new strategy reduces these negative side effects by depleting grafts of inexperienced, naïve T cells but retaining memory T cells, which protect against previously encountered pathogens. 

Marie Bleakley release"We are trying to find the balance between leaving all T cells in and risking GVHD and removing all T cells and making patients vulnerable to infections and cancer relapse,” said first author Marie Bleakley, MD, PhD, associate professor of pediatrics at University of Washington School of Medicine and Fred Hutchinson Cancer Research Center. “This technique of reducing naïve T cells works better than most competing approaches.”

Led by Bleakley, who holds the Gerdin Family Endowed Chair of Leukemia Research at Fred Hutch, the team recruited 138 leukemia patients, including both adults and children, across three phase II clinical trials. They collected circulating blood from healthy donors who were immunologically matched to each patient and used a reagent to remove naïve T cells. After chemotherapy and irradiation to kill cancer cells and make space for the transplant, patients received the naïve T cell-depleted graft.

According to Shlomchik, the most striking finding was that just 7% of patients developed chronic GVHD compared with previously reported rates of 30% to 60%. 

“Bench-to-bedside is almost a cliché, but we’ve taken this work from mouse studies in the lab all the way to patients in the clinic,” said Shlomchik, who also holds the Pittsburgh Foundation chair in cancer immunology. “Our patients are doing exceedingly well compared to those who received different treatment approaches reported in other studies, suggesting that naïve T cell depletion could be a broadly applicable strategy to reduce GVHD and improve outcomes.” 

“However, randomized trials comparing our approach to standard approaches are needed to definitively determine which are best,” he continued. “But even without randomized trials, we are confident that naïve T cell depletion reduces chronic GVHD.” 

Importantly, naïve T cell depletion did not appear to increase rates of leukemia relapse or fatal infections, although randomized control trials that compare different strategies are also needed to confirm these findings. The researchers have launched two such randomized phase II clinical trials for adult and pediatric leukemia patients. 

This research was supported by the National Institutes of Health (NIH; CA18029, CA15704, HL121568-01A1, CA 136551), the NIH Rapid Access to Intervention Development (project 298), the Damon Runyon Cancer Research Foundation, the Richard Lumsden Foundation (CI-57-11), the National Cancer Institute (K23CA154532), the Leukemia & Lymphoma Society, and the Burroughs Wellcome Fund.

Other authors on the study were Alison Sehgal, MD, of Pitt and UPMC; Stuart Seropian, MD, of Yale School of Medicine and Yale Cancer Center; Melinda A. Biernacki, MD, Elizabeth F. Krakow, MD, Ann Dahlberg, MD, Paul J. Martin, MD, Paul A. Carpenter, MBBS, Mary E. Flowers, MD, Theodore A. Gooley, PhD, Keith Loeb, MD, PhD, Stanley R. Riddell, MD, and Brent L. Wood, MD, PhD, of Fred Hutch and University of Washington; Heather Persinger, MA, Barbara Hilzinger, BSc, Jenna Voutsinas, MPH, and Shelly Heimfeld, PhD, of Fred Hutch.